Details:

Alternative Title:
Pharmacogenomics J
Personal Author:
Aminkeng, F; Ross, CJD; Rassekh, SR; Brunham, LR; Sistonen, J; ... More +
Aminkeng, F; Ross, CJD; Rassekh, SR; Brunham, LR; Sistonen, J; Dube, M-P; Ibrahim, M; Nyambo, TB; Omar, SA; Froment, A; Bodo, J-M; Tishkoff, S; Carleton, BC; Hayden, MR; Less -
Corporate Authors:
The Canadian Pharmacogenomics Network for Drug Safety Consortium;
Description:
There is established clinical evidence for differences in drug response, cure rates and survival outcomes between different ethnic populations, but the causes are poorly understood. Differences in frequencies of functional genetic variants in key drug response and metabolism genes may significantly influence drug response differences in different populations. To assess this, we genotyped 1330 individuals of African (n=372) and European (n=958) descent for 4535 single-nucleotide polymorphisms in 350 key drug absorption, distribution, metabolism, elimination and toxicity genes. Important and remarkable differences in the distribution of genetic variants were observed between Africans and Europeans and among the African populations. These could translate into significant differences in drug efficacy and safety profiles, and also in the required dose to achieve the desired therapeutic effect in different populations. Our data points to the need for population-specific genetic variation in personalizing medicine and care.
Subject:
[+]
Acquired Immunodeficiency Syndrome
Blacks
Drug-Related Side Effects And Adverse Reactions
Gene Frequency
Genetic Predisposition To Disease
Genetic Variation
Humans
Neoplasms
Polymorphism, Single Nucleotide
Tuberculosis
Whites

Source:
Pharmacogenomics J. 14(2):160-170.;
Pubmed ID:
23588107
Pubmed Central ID:
PMC4684079
Document Type:
Journal Article;
Funding:
8 DP1 ES022577-04/DP/NCCDPHP CDC HHS/United States; DP1 ES022577/ES/NIEHS NIH HHS/United States; R01 GM076637/GM/NIGMS NIH HHS/United States; R01GM076637/GM/NIGMS NIH HHS/United States; Canadian Institutes of Health Research/Canada;
8 DP1 ES022577-04/DP/NCCDPHP CDC HHS/United States; DP1 ES022577/ES/NIEHS NIH HHS/United States; R01 GM076637/GM/NIGMS NIH HHS/United States; R01GM076637/GM/NIGMS NIH HHS/United States; Canadian Institutes of Health Research/Canada; Less -
Collection(s):
CDC Public Access
Main Document Checksum:
[+]
urn:sha256:ad062da8951f3f841e1eadfc1b94a9757da28f7fb08fa47007c0e84c3ce2f6c7
File Type:

Supporting Files

• 	NIHMS740102-supplement-Supplementary_Table_1.xls	xls
  	NIHMS740102-supplement-Supplementary_Table_2.xls	xls
  	NIHMS740102-supplement-Supplementary_Table_3.xls	xls
  	NIHMS740102-supplement-Supplementary_Table_4.xls	xls
  	NIHMS740102-supplement-Supplementary_Table_5.xls	xls
  	nihms740102.nxml	bin

More +